HomeAI · summaries
Storia in 3 fonti
PAM Inhibitor Approved for HR-Positive Breast Cancer
Gedatolisib is approved in combination with fulvestrant, with or without palbociclib
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
medpagetoday.com
PAM Inhibitor Approved for HR-Positive Breast Cancer
Gedatolisib is approved in combination with fulvestrant, with or without palbociclib
- ·
healio.com
FDA approves Revtorpyk for hormone receptor-positive, HER2-negative breast cancer
The FDA has approved a new targeted therapy combination for the most common subtype of breast cancer.Gedatolisib (Revtorpyk, Celcuity Inc.) plus fulvestrant, with or without…
